WO2017082479A1 - Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée - Google Patents

Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée Download PDF

Info

Publication number
WO2017082479A1
WO2017082479A1 PCT/KR2016/002069 KR2016002069W WO2017082479A1 WO 2017082479 A1 WO2017082479 A1 WO 2017082479A1 KR 2016002069 W KR2016002069 W KR 2016002069W WO 2017082479 A1 WO2017082479 A1 WO 2017082479A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
composition
obesity
soybean
fat
Prior art date
Application number
PCT/KR2016/002069
Other languages
English (en)
Korean (ko)
Inventor
서우덕
강현중
이미자
김선림
Original Assignee
대한민국(농촌진흥청장)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 대한민국(농촌진흥청장) filed Critical 대한민국(농촌진흥청장)
Publication of WO2017082479A1 publication Critical patent/WO2017082479A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae

Definitions

  • the present invention relates to a pharmaceutical composition for the prevention or treatment of obesity comprising soybean germination extract, specifically, a composition for the prevention or treatment of obesity comprising soybean germination extract or a fraction thereof, the composition except the human It relates to a method for preventing or treating obesity, comprising the step of administering to, a food composition for preventing or improving obesity, including a soybean germ extract or a fraction thereof, and a feed composition.
  • Obesity or obesity is a state in which fat is excessively accumulated in the body, which is a general term for a state in which fat is increased due to an increase in the number of adipocytes in adipocytes or an increase in the size of adipocytes.
  • Obesity itself may not be a problem, but the social complications caused and the secondary complications caused by excess fat are severe.
  • obesity causes diseases such as hypertension, hyperlipidemia, heart disease, diabetes, arteriosclerosis, fatty liver, joint abnormalities, arthritis, sexual dysfunction, and cancer.
  • fat cells are reduced in size, and because they are not naturally removed and remain in the body permanently, interest for the prevention and treatment of obesity is increasing.
  • the development of anti-obesity drugs with low toxicity and side effects are urgently required, and recently, alternative methods or preparation methods of various extracts using active ingredients derived from natural products such as herbal medicines and foods have been studied.
  • the composition for the prevention and treatment of obesity including the extract of the herbal medicine (Korean Patent Publication No. 2015-0105563) or the composition for the improvement, prevention or treatment of obesity, including garlic and Yeoju extract (Korea Patent Publication 2015- 0085543) has been developed.
  • the development of a natural pharmaceutical composition or its raw material which is superior to existing synthetic pharmaceutical compositions for obesity and has fewer side effects, has yet to be developed.
  • the present inventors have diligently researched to develop a therapeutic agent for obesity using natural-derived ingredients.
  • the extract of soybean germination embryos produced by germinating soybean embryos discarded in the manufacturing process of processed products using soybeans suppresses the differentiation of fat cells.
  • the present invention was completed.
  • One object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity comprising soybean germ extract or fractions thereof.
  • Another object of the present invention is to provide a method for preventing or treating obesity, comprising administering the composition to a subject other than a human.
  • Another object of the present invention to provide a food composition for the prevention or improvement of obesity comprising soybean germ extract or fractions thereof.
  • Another object of the present invention is to provide a feed composition for the prevention or improvement of obesity comprising soybean germ extract or fractions thereof.
  • the soybean germ extract of the present invention inhibits the differentiation of adipocytes, reduces the size, and inhibits the accumulation of unnecessary fat in vivo by converting white adipocytes into brown adipocytes, and thus can be usefully used for the prevention or treatment of obesity. Can be.
  • 1 is a graph showing the toxicity of soybean germ extract to the fat precursor cell line 3T3-L1. Soybean germ extracts were treated at concentrations of 50, 100, 200, 300, 400 and 500 ⁇ g / mL.
  • soybean germ extracts were prepared at concentrations of 50, 100, 200, 300, 400 and 500 ⁇ g / mL and treated with the cells, and 100 ⁇ M of CLA (conjugated linoleic acid) as a positive control. ).
  • Control refers to undifferentiated control adipocytes
  • control + insulin refers to differentiated control adipocytes.
  • Soybean germination extract was prepared at a concentration of 500 ⁇ g / mL and treated to the cells.
  • FIG. 3 shows the effect of soybean germination extract (SA) and soybean germination extract (SG) on gene expression associated with adipocyte differentiation
  • A is a Western blot image showing the amount of gene expression
  • B is the expression amount
  • This graph shows the result of quantification.
  • PPAR ⁇ , SREBP-1c and CEBP ⁇ are genes that promote differentiation of adipocytes, and Actin gene was used as a control for comparing expression levels of the genes.
  • Figure 4 shows the effect of soybean germ extract on fat cell size
  • A is an image showing the size of fat cells
  • B is a graph showing the result of measuring the size.
  • Obesity-induced mice (OVX) were surgically removed and used as a negative control group. Soybean germination ingestion was administered to the mice with 0.1 mg / kg, 1 mg / kg and 5 mg / kg soybean germ extracts. Used as a group.
  • FIG. 5 shows the effect of soybean germ extract on white fat cells and brown fat cells
  • A is an image showing the size of white fat cells
  • B is a measure of the number of brown fat cells to the number of white fat cells
  • This graph shows the results.
  • Obesity-induced mice (OVX) were surgically removed and used as a negative control group. Soybean germination ingestion was administered to the mice with 0.1 mg / kg, 1 mg / kg and 5 mg / kg soybean germ extracts. Used as a group.
  • One aspect for achieving the above object provides a pharmaceutical composition for the prevention or treatment of obesity comprising soybean germ extract or fractions thereof.
  • soybean germination embryo refers to a germinated embryo that germinates an embryo isolated from soybean.
  • the method for producing soybean germ has been known by the inventors' prior studies (Korean Patent Laid-Open No. 2013-0057173), and specifically, the soybean germ may be obtained by germinating embryos separated from soybeans. It is not limited to this.
  • the anti-obesity effect of the soybean germ extract was not known at all, and was first identified by the present inventors.
  • the soybean germ extract of the present invention may be obtained by extracting the soybean germ with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
  • extract refers to an extract obtained by extracting soybean germ, a diluent or concentrate of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof. It includes the extract itself and extracts of all formulations that can be formed using the extract.
  • the method of extracting the soybean germination embryo is not particularly limited, and may be extracted according to a method commonly used in the art.
  • the kind of the extraction solvent used to extract the soybean germ in the present invention is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the extraction solvent may include water, alcohol or a mixed solvent thereof, these may be used alone or may be used in combination of one or more.
  • alcohol specifically, the C1-C4 alcohol can be used.
  • fraction refers to the result obtained by performing fractionation to separate a specific component or a specific component group from a mixture comprising various various components.
  • the fractionation method of obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art.
  • a method of obtaining a fraction from the extract by treating the extract obtained by extracting the soybean germination of the present invention with a predetermined solvent is not particularly limited, and may be performed according to a method commonly used in the art.
  • the kind of the fractionation solvent used to obtain the fraction in the present invention is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the fractionation solvents include polar solvents such as water and alcohols; And nonpolar solvents such as hexane, ethyl acetate, chloroform, dichloromethane, and the like. These may be used alone or in combination of one or more.
  • polar solvents such as water and alcohols
  • nonpolar solvents such as hexane, ethyl acetate, chloroform, dichloromethane, and the like. These may be used alone or in combination of one or more.
  • alcohol in the fractionation solvent an alcohol having 1 to 4 carbon atoms may be used.
  • Soybean germination extract of the present invention may be to inhibit the differentiation of fat cells.
  • the term "differentiation of adipocytes” means the conversion of adipocytes into adipocytes, and for the purposes of the present invention, means adipocytes accumulate fat in cells.
  • soybean germination extract was confirmed to reduce fat contained in fat cells to a similar degree as the experimental group treated with CLA (conjugated linoleic acid), which is also used as a dietary supplement It was confirmed that the effect is better than the extract obtained by germinating itself (Fig. 2). This suggests that the extract has an effect of removing excess accumulated fat and thus can be effectively used for treating obesity.
  • CLA conjugated linoleic acid
  • soybean germination extract of the present invention may be to reduce the size of fat cells.
  • the term "size of fat cells” means the diameter of fat cells. Since the size of the cell is determined by the amount of fat accumulated in the cell, the decrease in the size of the adipocyte may be a decrease in the amount of fat in the cell.
  • soybean germination extract of the present invention may be to convert white fat cells into brown fat cells.
  • white adipocyte refers to a fat cell that stores fat and is a cell that causes adult diseases such as diabetes and obesity.
  • brown adipocyte refers to a cell that burns fat into energy and is a cell that plays an important role in thermoregulation and energy production.
  • the extract has an effect of inhibiting the accumulation of fat by converting white fat cells into brown fat cells, and thus can be effectively used for treating obesity.
  • the term "obesity” means a state in which adipose tissue is excessive in the body. Men are said to be obese when their body fat is more than 25% of their body weight, and women are more than 30% of their body weight, and obesity occurs when the amount of calories consumed by food is greater than the calories they consume. Obesity can appear fat and seem easy to breathe, joint pain, diabetes, hypertension and other symptoms can be accompanied.
  • prevention means any action that inhibits or delays obesity by administration of a pharmaceutical composition comprising the extract of the present invention.
  • treatment refers to any action by which administration of the pharmaceutical composition improves or advantageously alters the symptoms of a suspected and obese individual.
  • the pharmaceutical composition of the present invention may include 0.0001 to 50% by weight of the extract relative to the total weight of the composition, and may specifically include 0.01 to 10% by weight, but is not limited thereto.
  • the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent commonly used in the manufacture of the pharmaceutical composition, and the carrier may include a non-naturally occuring carrier. Can be.
  • pharmaceutically acceptable in the present invention means to exhibit properties that are not toxic to cells or humans exposed to the composition.
  • the pharmaceutical composition may be formulated in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods.
  • sterile injectable solutions such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to conventional methods.
  • carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • Solid form preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid form forms at least one excipient such as starch, calcium carbonate, sucrose or lactose. (lactose), gelatin, etc. are mixed and prepared.
  • lubricants such as magnesium styrate and talc are also used.
  • Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • the non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • One aspect for achieving the above object provides a method for preventing or treating obesity comprising administering the composition to a subject other than a human.
  • administration means introducing a certain substance into an individual in a suitable manner.
  • the term "individual" of the present invention means all animals, such as rats, mice, livestock, and the like, including humans who may or may develop obesity. As a specific example, it may be a mammal including a human.
  • the method for preventing or treating obesity may include administering a pharmaceutical composition for preventing or treating obesity, including a soybean germination extract or a fraction thereof, to an individual except a human in a pharmaceutically effective amount. have.
  • the term “pharmaceutically effective amount” means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to medical treatment and that does not cause side effects, and the effective dose level is the sex, age of the patient.
  • other medical fields including body weight, health status, type of disease, severity, drug activity, drug sensitivity, method of administration, time of administration, route of administration, and rate of release, duration of treatment, combination or drug used It can be easily determined by those skilled in the art according to factors well known in the art.
  • composition of the present invention may be administered at 0.0001 to 100 mg / kg body weight per day, more specifically at 0.001 to 100 mg / kg body weight, based on solids. Dosing may include administering the recommended dose once daily, or in divided doses.
  • the route of administration and the mode of administration of the composition are not particularly limited, and any route of administration and administration can be achieved as long as the composition comprising the composition can reach the desired site. You can follow the way.
  • the composition may be administered through various routes, oral or parenteral, and non-limiting examples of the route of administration include oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, nasal What is administered through intralateral or inhalation etc. are mentioned.
  • One aspect to achieve the above object provides a food composition for the prevention or improvement of obesity comprising soybean germ extract or fractions thereof.
  • improvement means any activity in which obesity is improved or advantageously changed by administration of the composition.
  • the term "food” of the present invention meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages , Vitamin complexes, nutraceuticals and health foods, and includes all foods in the usual sense.
  • the functional food is the same term as a food for special health use (Food for special health use, FoSHU), in addition to the nutritional supply, the processed food, so that the bioregulatory function appears efficiently, high medical effect Means food.
  • Food for special health use Food for special health use, FoSHU
  • the term 'function' means to obtain useful effects on health use such as nutrient control or physiological action on the structure and function of the human body.
  • the food of the present invention may be prepared by a method commonly used in the art, and the preparation may be performed by adding raw materials and ingredients commonly added in the art.
  • the formulation of the food may also be prepared without limitation as long as the formulation is recognized as a food.
  • Food composition of the present invention can be prepared in various forms of formulation, unlike the general medicine has the advantage that there is no side effect that can occur when taking a long-term use of the drug as a raw material, and excellent portability, the present invention Foods can be taken as a supplement to enhance the effect of preventing or improving obesity.
  • the health food refers to foods having active health maintenance or promotion effect as compared to general foods
  • the health supplement food refers to foods for health supplementation purposes.
  • nutraceutical, health food, dietary supplement are used.
  • the health functional food is a food prepared by adding the extract of the present invention to food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc.
  • food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc.
  • the food composition of the present invention can be consumed on a daily basis, since a high effect can be expected for the prevention or improvement of obesity, it can be very usefully used.
  • the food composition may further include a physiologically acceptable carrier, and the type of carrier is not particularly limited and may be any carrier that is commonly used in the art.
  • the food composition may include additional ingredients that are commonly used in food compositions to improve the smell, taste, time and the like.
  • additional ingredients may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like.
  • minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) and chromium (Cr) may be included. It may also contain amino acids such as lysine, tryptophan, cysteine, valine and the like.
  • the food composition is a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetic acid, etc.), fungicides (bleaching powder and highly bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisol (BHA), butylhydride) Oxytoluene (BHT), etc.), colorant (such as tar pigment), colorant (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (MSG glutamate, etc.), sweetener (ducin, cyclate, saccharin Foods such as sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, potassium D-tartrate, etc.), reinforcing agents, emulsifiers, thickeners (foils), coatings, gum herbicides, foam inhibitors, solvents, modifiers It may include food additives.
  • the additive may be selected according to
  • the extract of the present invention may be added as it is or used with other food or food ingredients, and may be appropriately used according to conventional methods.
  • the mixed amount of the active ingredient can be suitably determined according to the purpose of use (prevention, health or therapeutic treatment).
  • the food composition of the present invention may be added in an amount of 50 parts by weight or less, specifically 20 parts by weight or less based on the food or beverage in the manufacture of food or beverage.
  • the active ingredient may be used in an amount above the above range.
  • An example of the food composition of the present invention may be used as a health beverage composition, in which case it may contain various flavors or natural carbohydrates and the like as additional ingredients, such as a general beverage.
  • the above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin, cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol.
  • Sweeteners include natural sweeteners such as taumartin, stevia extract; Synthetic sweeteners such as saccharin and aspartame;
  • the ratio of the natural carbohydrate may generally be about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g, per 100 mL of the health beverage composition of the present invention.
  • the health beverage composition includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, Alcohol or carbonation agent and the like.
  • Others may contain fruit flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components can be used independently or in combination. Although the ratio of such an additive is not critical, it is generally selected from the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.
  • Food composition of the present invention may include a variety of weight percent if it can exhibit the effect of preventing or improving obesity, specifically, the extract of the present invention to 0.00001 to 100% by weight or 0.01 to 80% by weight relative to the total weight of the food composition It may include, but is not limited thereto.
  • One aspect for achieving the above object provides a feed composition for the prevention or improvement of obesity comprising soybean germ extract or fractions thereof.
  • feed means any natural or artificial diet, meal, or the like or component of such meal for the animal to eat, ingest, and digest.
  • the feed may comprise feed additives or feed supplements.
  • the kind of the feed is not particularly limited, and may be used a feed commonly used in the art.
  • Non-limiting examples of the feed may include plant feeds such as cereals, fruits, food processing by-products, algae, fibres, pharmaceutical by-products, oils, starches, gourds or grain by-products; And animal feeds such as proteins, minerals, fats and oils, minerals, fats and oils, single cell proteins, zooplankton or foods. These may be used alone or in combination of two or more thereof.
  • soybean germ was prepared according to the previous study of the present inventors. Specifically, soybean embryos were immersed in running water to germinate, and soybean germ embryos were harvested and lyophilized at about 24 hours, and powdered to obtain soybean germ powder. Fermented alcohol was added to the soybean germination powder thus obtained, followed by filtration to obtain a liquid component, and the liquid component was lyophilized to obtain a soybean germination extract.
  • the cytotoxicity of the extract against the cells was evaluated. Specifically, the progenitor cell lines 3T3-L1 were counted at 2 ⁇ 10 2 cells / well in 96 well plates, and the soybean germ extracts of 50, 100, 200, 300, 400 and 500 ⁇ g / mL concentrations were divided into the cells. Treated and incubated for 24 or 72 hours. After completion of the incubation, the water-insoluble formazan formed by the addition of the MTT solution was dissolved in a dimethyl sulfoxide solution, and the absorbance of the dissolved formazan was measured at 595 nm (optical density; OD value). Relative cell activity (%) was evaluated by measuring.
  • the soybean germ extract of the present invention is a safe substance without harm to the human body.
  • soybean germination extract In order to confirm the anti-obesity effect of the extract, the effect of soybean germination extract on the degree of adipocyte differentiation was analyzed.
  • 3T3-L1 cells (Korean Cell Line Bank, Korea) were purchased as 10% FBS (fetal bovine serum) and 1% antibiotic (antibiotics; 100 U / ml of penicillin and 0.1 mg / mL of steeptomycin). ) was incubated at 37 ° C. under 5% CO 2 (95% air) using DMEM (Dulbecco's modified eagle medium) medium.
  • FBS fetal bovine serum
  • antibiotic antibiotics
  • soybean germ extract prepared in the cultured 3T3-L1 cells was treated to the cells at concentrations of 50, 100, 200, 300, 400 and 500 ⁇ g / mL, and differentiated derivatives (FBS, IBMX, dexanmethasone and Insulin) was cultured in a medium containing 72 hours for differentiation into adipocytes.
  • differentiated derivatives FBS, IBMX, dexanmethasone and Insulin
  • the control group was used as an adipocyte not treated with any substance
  • the comparison group was used as an adipocyte treated with the same concentration of CLA (conjugated linoleic acid).
  • the insulin-differentiated control adipocytes (control + insulin) was confirmed to increase the fat accumulated in the cells.
  • the soybean germination extract was confirmed to reduce the fat contained in the differentiated fat cells to a similar degree as the experimental group treated with CLA (conjugated linoleic acid), which is also used as a dietary supplement. It was confirmed that the fat reduction effect of the better the higher the concentration of the extract.
  • the soybean germination extract of the present invention when compared with the extract obtained by germinating the beans themselves, it was confirmed that the effect of inhibiting adipocyte differentiation is more excellent, and thus also the effect of inhibiting fat accumulation.
  • Example 2-2 Effect of Soybean Germination Extract on Adipocyte Differentiation
  • PPAR ⁇ , SREBP-1c and CEBP ⁇ which are genes that promote the differentiation of adipocytes.
  • the ovarian was removed using 8-week-old female C57BL / 6 mice to prepare a postmenopausal osteoporosis disease animal. After removal of the skin from the lower abdomen by 1-2cm, the ovary was used by forceps. ovary and oviducts were towed and excised. After one week of ovarian removal, randomized grouping was divided by weight measurement, and oral administration of soy germination embryo extract 0.1, 1 and 5 mg / kg 6 times a week using Sonde.
  • 10% formalin fixation was performed by removing the adipose tissue around the uterine tissue, and the adipose tissue was sectioned to 4 ⁇ m through paraffin immobilization. Then, the microscope was performed with an optical microscope through HE (Hematoxylin and Eosin) staining. Specifically, the fat cells were observed at 400 times magnification, and the long and short axis lengths were measured for 10 cells in one field of view. The mean value of the major and minor axis observed at 3 o'clock per individual was calculated, and the average value of the group was calculated.
  • HE Hematoxylin and Eosin
  • the obesity-induced obesity-induced negative control compared to the normal control (con) it was confirmed that both shortening and long axis length of fat cells increased.
  • the experimental group administered with the extract was confirmed that the diameter of the adipocytes decreased compared to the negative control, this effect was better as the concentration of the extract was higher, the higher concentration of the extract (5mg / kg / day) In the experimental group administered, it was confirmed that the size of the adipocytes decreased to a level similar to the normal control group.
  • Example 3-2 Effect of Soybean Germination Extract on White Adipocytes and Brown Adipocytes
  • White fat cells are the cause of adult diseases such as diabetes or obesity, whereas brown fat cells play a role of preventing fat by burning fat with energy, so to evaluate the therapeutic effect of the extract, soybean germination embryo extract The effect of this ovary removal on white fat cells or brown fat cells in the obese animal model was analyzed.
  • the bean germination embryo extract was administered to the obesity-induced animal model by the method according to Example 3-1, and the number of white fat cells and brown fat cells of the animal was investigated.
  • Fatty tissue cells undergo immunohistochemical staining using UCP1 (Mitochondrial uncoupling protein 1) protein involved in fatty acid oxidation, and then brown fat cells showing UCP1 positive response at 3 visual fields per microscope at 200-fold magnification. The number of was measured using LAS image analysis software.
  • UCP1 Mitochondrial uncoupling protein 1
  • the negative control group (OVX) and the normal control group (con) induced by obesity due to menopause confirmed that the number of cells showing UCP1 positive response in and around gonadal fat was small.
  • the experimental group administered with the extract was confirmed to increase the number of cells showing a UCP1 positive response compared to the negative and normal control, it was confirmed that the size of the white adipocytes decreases at the same time. This effect was better as the concentration of the extract was higher, the experimental group administered the high concentration of the extract (5mg / kg / day), the number of brown fat cells compared to the control group did not receive about 3.2 times the increase was confirmed It was.
  • the soybean germ extract has an effect of inhibiting the accumulation of fat by reducing the size of the white fat cells and browning the cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)

Abstract

La présente invention concerne une composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée et, plus précisément, une composition pharmaceutique pour prévenir ou traiter l'obésité comprenant un extrait embryonnaire de fève germée ou une fraction de cette dernière, un procédé pour prévenir ou traiter l'obésité comprenant une étape consistant à administrer la composition à un sujet non humain, et une composition alimentaire et une composition d'aliments pour bétail pour prévenir ou améliorer l'obésité comprenant un extrait embryonnaire de fève germée ou une fraction de ce dernier. L'extrait embryonnaire de fève germée de la présente invention inhibe la différenciation d'adipocytes et réduit leur taille, et convertit des adipocytes blancs en adipocytes bruns, supprimant ainsi l'accumulation de graisse superflue in vivo et, par conséquent, peut être utilisé efficacement pour prévenir ou traiter l'obésité.
PCT/KR2016/002069 2015-11-09 2016-03-02 Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée WO2017082479A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0156867 2015-11-09
KR1020150156867A KR101749967B1 (ko) 2015-11-09 2015-11-09 콩 발아배아 추출물을 포함하는 비만의 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
WO2017082479A1 true WO2017082479A1 (fr) 2017-05-18

Family

ID=58695668

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/002069 WO2017082479A1 (fr) 2015-11-09 2016-03-02 Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée

Country Status (2)

Country Link
KR (1) KR101749967B1 (fr)
WO (1) WO2017082479A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190104819A (ko) 2018-03-02 2019-09-11 (주)셀턴 콩 배아에서 추출된 이소플라본/소야사포닌 복합물을 포함하는 유기산 글리세린 에스테르의 제조 방법 및 이를 포함하는 화장료 조성물
KR102130534B1 (ko) 2018-11-05 2020-07-06 (주)화인에프티 콩 발아 배아 추출물을 함유하는 선식의 제조방법.
KR20200061836A (ko) 2018-11-26 2020-06-03 (주)비티엔 핵산이 포함된 주름 개선용 기능성 식품 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005145826A (ja) * 2003-11-11 2005-06-09 Kazuhiro Kotani 発芽豆を含む生活習慣病の予防および／または治療用組成物
KR100706279B1 (ko) * 2005-11-11 2007-04-12 (주)아모레퍼시픽 쿠메스트롤을 함유한 비만 개선 및 예방용 조성물
KR20120003693A (ko) * 2010-07-05 2012-01-11 주식회사 엘지생활건강 적포도 추출물, 녹차 추출물, 대두 추출물 및 ｌ－카르니틴을 유효성분으로 함유하는 항비만 조성물
KR20140131881A (ko) * 2013-05-06 2014-11-14 (주)아모레퍼시픽 쿠메스트롤을 포함하는 콩 추출물을 유효성분으로 포함하는 갱년기 증상의 예방 및 치료용 조성물
KR20140141871A (ko) * 2013-05-31 2014-12-11 고려대학교 산학협력단 발아 콩 펩타이드를 유효성분으로 포함하는 항비만 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005145826A (ja) * 2003-11-11 2005-06-09 Kazuhiro Kotani 発芽豆を含む生活習慣病の予防および／または治療用組成物
KR100706279B1 (ko) * 2005-11-11 2007-04-12 (주)아모레퍼시픽 쿠메스트롤을 함유한 비만 개선 및 예방용 조성물
KR20120003693A (ko) * 2010-07-05 2012-01-11 주식회사 엘지생활건강 적포도 추출물, 녹차 추출물, 대두 추출물 및 ｌ－카르니틴을 유효성분으로 함유하는 항비만 조성물
KR20140131881A (ko) * 2013-05-06 2014-11-14 (주)아모레퍼시픽 쿠메스트롤을 포함하는 콩 추출물을 유효성분으로 포함하는 갱년기 증상의 예방 및 치료용 조성물
KR20140141871A (ko) * 2013-05-31 2014-12-11 고려대학교 산학협력단 발아 콩 펩타이드를 유효성분으로 포함하는 항비만 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SBS NEWS: "Geminated Bean Extract, Effective for Alleviating climacteric symptoms", 3 September 2015 (2015-09-03), Retrieved from the Internet <URL:http://news.sbs.co.kr/news/andPagedo.9nam.--id=N1003153373&plink-ORI&cooper=NAVER> *

Also Published As

Publication number Publication date
KR101749967B1 (ko) 2017-06-23
KR20170054116A (ko) 2017-05-17

Similar Documents

Publication Publication Date Title
WO2017039365A1 (fr) Méthode d&#39;inhibition de l&#39;absorption et/ou de promotion de l&#39;excrétion de lipides à l&#39;aide de d-psicose
WO2015002391A1 (fr) Composition présentant une fonction d&#39;atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2016060426A1 (fr) Composition contenant un extrait de dolichos lablab l. comme principe actif pour prévenir ou soulager une stéatose hépatique non alcoolique
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d&#39;atractylis, de mori fructus, de lyciet commun, de longane, d&#39;achyranthes, d&#39;écorce d&#39;eucommia et d&#39;asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2017082479A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de l&#39;obésité comprenant un extrait embryonnaire de fève germée
WO2012008788A2 (fr) Composition contenant de la sérine en tant que principe actif pour la prévention et le traitement de stéatoses hépatiques, et utilisation de celle-ci
WO2017116045A1 (fr) Composition destinée à prévenir et traiter un trouble du climatère contenant des extraits de dendropanax morbifera lev. comme principe actif
WO2017082478A1 (fr) Composition pharmaceutique visant à prévenir ou traiter l&#39;ostéoporose et contenant un extrait de germe de soja
WO2017146486A1 (fr) Composition destinée à prévenir ou traiter l&#39;hyperplasie bénigne de la prostate contenant de l&#39;extrait de morus alba linnaeus
WO2013069934A1 (fr) Composition pour traiter et prévenir l&#39;obésité, contenant de l&#39;extrait d&#39;agropyre comme principe actif
KR102081984B1 (ko) 새싹밀 추출물을 포함하는 골다공증 예방 또는 치료용 조성물
WO2019212300A1 (fr) Composition comprenant un extrait d&#39;aster koraiensis nakai ou une fraction de celui-ci en tant que principe actif pour la prévention ou le traitement de la maladie de parkinson
KR102075836B1 (ko) 마키베리 추출물, 당귀 추출물 및 시계꽃 추출물을 유효성분으로 함유하는 갱년기 증상 예방 또는 치료용 조성물
WO2023003204A1 (fr) Composition anti-obésité contenant un extrait de rosa davurica en tant que principe actif
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d&#39;une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
KR101445966B1 (ko) 백두구 추출물을 포함하는 항비만 조성물
KR20180000586A (ko) 콩 발아배아 추출물을 포함하는 대사성 질환의 예방 또는 치료용 약학 조성물
WO2018066956A1 (fr) Composition comprenant un extrait composite contenant du schisandrae fructus pour prévenir ou traiter une maladie liée à la circulation sanguine
KR101084942B1 (ko) 천우슬을 이용한 관절염 치료제
KR101851639B1 (ko) 모과 추출물 또는 이의 분획물을 유효성분으로 함유하는 항비만용 조성물
JP2014185088A (ja) 経口組成物、脂肪細胞分化抑制剤および飲食品
KR102014922B1 (ko) 감초 유래 글라블리딘을 유효성분으로 하는 소화기능 개선용 조성물
WO2020122373A1 (fr) Composition comprenant un extrait de glycyrrhiza uralensis en tant que principe actif pour la prévention, l&#39;atténuation ou le traitement du syndrome d&#39;hypogonadisme d&#39;apparition tardive
WO2018008999A1 (fr) Composition comprenant un extrait d&#39;aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète
KR102380295B1 (ko) 귀리 추출물을 포함하는 근감소증 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16864405

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16864405

Country of ref document: EP

Kind code of ref document: A1